Qrons (QRON) Total Assets : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Qrons Total Assets?

Qrons's Total Assets for the quarter that ended in Mar. 2024 was $0.00 Mil.

Total Assets is connected with ROA %. Qrons's annualized ROA % for the quarter that ended in Mar. 2024 was -4,300.00%. Total Assets is also linked to Revenue through Asset Turnover. Qrons's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Qrons Total Assets Historical Data

The historical data trend for Qrons's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qrons Total Assets Chart

Qrons Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

0.12

0.06

0.04

Qrons Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															-	0.01	0.01	-	-

Qrons Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Qrons's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-1.488	+	1.489
	=	0.00

Qrons's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-1.471	+	1.475
	=	0.00

Qrons (OTCPK:QRON) Total Assets Explanation

Total Assets is connected with ROA %.

Qrons's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-0.172	/	( (0	+	0.004)	/ 1 )
	=	-0.172	/	0.004
	=	-4,300.00 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Qrons's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (0	+	0.004)	/ 1 )
=	0	/	0.004
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Qrons Total Assets Related Terms

Thank you for viewing the detailed overview of Qrons's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Qrons (QRON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

28-10 Jackson Avenue, No. 26N, Long Island City, New York, NY, USA, 11101

Website

https://www.qrons.com

Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The firm has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.

Executives

John N Bonfiglio	officer: Chief Operating Officer	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer	director, 10 percent owner, officer: CEO, CFO and Secretary	28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld	director, 10 percent owner, officer: President	153 HAGILBOA STREET, NIRIT L3 44805